Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy designed to lower the production of lipoprotein ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically ...

Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.